Atlas Venture’s Post

A New Biotech Accelerator in Europe?... yes we have. 🚀 Sofinnova Partners is shaking things up in the biotech startup scene across Europe with their new investment strategy called Biovelocita. With Biovelocita, they've put together a top-notch team dedicated to providing hands-on support and financial backing to startups. This team brings a wealth of experience, including serial entrepreneurs and seasoned investors, who will collaborate with leading academic institutions. Key partners of this initiative include: - Maria Gabriella Camboni - co-founder and CEO of BiovelocITA - Matthieu Coutet - Partner with significant contributions to the launch of biotech startups such as Therachon and Annapurna Therapeutics - Alex Leech - founding CEO of Alchemab Therapeutics Ltd - Zhizhong "Joel" Y. - a former Principal in the Sofinnova Capital Strategy, and a Kauffman Fellows As one of the leading investors in Health Tech Europe, Sofinnova Partners continues to pave the way for innovation in the industry. Check out this article (👉 https://lnkd.in/eJ7PAaqG) for a glimpse into the top 25 most active investors in Health Tech in Europe, covering investments from Seed to Series A. 🌱💼 Enjoy the read! #Biotech #HealthTech #startups

🚀 Elevate Your Biotech Startup IP Strategy! 🧬 Join our event on "IP Strategy for Biotech Startups" and 𝐝𝐫𝐨𝐩 𝐲𝐨𝐮𝐫 𝐐𝐬 https://lnkd.in/eBKpNN95, and we will ensure 𝐲𝐨𝐮 𝐠𝐞𝐭 𝐭𝐡𝐞 𝐚𝐧𝐬𝐰𝐞𝐫𝐞𝐝! 🔑 Key Takeaways: Learn from experts 🧪 Q&A session 🙋♂️🙋♀️ Networking opportunities 🤝 🔗 Register now 👇 #biotech #startups #IPStrategy 🌟

Science-based start-ups and spinouts are often aware (you should be anyway!) that intellectual property (IP) is critical to the success of their business. But most of you are not IP experts, so what can you do as a startup/founder to get cracking with you IP, when you have very little money (other than chat to me!)? But you need the IP to get the money...but you have no money for the IP..but... Did you know that there is funding available for you to have an IP Audit done? Something which captures your IP as it is and how we think it will be? Something that is attractive to investors, turning your nebulous ideas and plans into an actual THING that can in some instances be shared in your dataroom? If not, check out this webinar between Potter Clarkson, the Industrial Biotechnology Innovation Centre (IBioIC), and Highlands and Islands Enterprise as we try to help you begin your IP journey and explain what each of us can offer, with a focus on the IP Audit funding. https://lnkd.in/eqAgJxUZ We will explore opportunities to combine early-stage funding, government support and specialist advice to help you take your first steps towards an IP audit. We will also hear from two founders who have been through the process and lived to tell the tale - giant thanks to Jessica Giannotti SeaDyes Limited and Dr Alicia Showering BugBiome #syntheticbiology #biotechnology #innovation #vc #founders #startups #spinouts

That's a wrap for LSX - partnering for Life Science eXecutives USA! Great conference with even better meetings. And Boston's Indian Summer made it even more special 🌞 Key insight: the funding 'Ice Age' seems to be improving and in 2024, back to normal. Let's hope for the best and plan for the worst ☝️ #biotech #startups

If you're looking to become more engrained in the #biotech community here in #Boston and #NewEngland, check out resources highlighted here: https://lnkd.in/e6JZHwvG This post breaks down: 📲 Movers & shakers in the biotech space 🤝 Networking groups & events for those interested specifically in biotech ↗️ Accelerators and incubators for biotech #startups 💰 #Investors in biotech What else should be highlighted? Let us know in the comments below! 👇

A collaboration with a pharma or medtech company might provide your start-up with access to funding, resources, expertise, or networks. Due diligence is a crucial step in forging such a collaboration. What can you expect and how do you set your start-up up for success? Join this session hosted by Johnson & Johnson Innovation’s Science & Partnering Forum – JLABS to explore the intricacies of due diligence. The program includes: ✅ Step-by-step guidance on navigating the due diligence process ✅ Insights from industry insiders and experts ✅ Real-life experiences shared by successful entrepreneurs Innovators can register here: https://lnkd.in/eAbDC-3t #Biotech #medtech #startups #jnjinnovation #lifesciences #pharma #lifeport #innovation #duediligence #collaboration

FYI for my early stage biotechs: it’s never too early to have a conversation about options for procuring lab equipment. A lot of the people I've talked to recently have been very early stage, either just starting their operations or just securing their first rounds of funding. They’re not ready to move forward with equipment anytime in the near future, but they know it’s important to know what their options are for making it happen. This is 100% ok. It’s never too early. There’s no pressure to make anything happen. And we’re always happy to equip you with whatever information/connections/insights we can to support whatever path ends up working best for you. So just a reminder, we don’t bite, and we love supporting early stage companies, even if we end up not being the right answer. :) #biotechnology #startups #lifesciences

🌱 Ready to turn your agrifood biotech innovation into reality? 🚀 Check out the open call for aspiring agrifood biotech startups looking to transform their innovation into an impactful business.

We can’t wait to welcome Venture Leaders Biotech 2024 to #Boston this May! The Venture Leaders Biotech roadshow brings Switzerland’s most innovative #biotech startups to Boston, one of the world’s leading #lifesciences hubs. The Venture Leaders Biotech 2024 are: > Adoram Therapeutics > #AllegriaTherapeutics > EVIIVE > inSEIT > KYLYS AESTHETICS SA > OBaris > Shape Biopharmaceuticals Inc. > TissueLabs > Well Science AG > Ymmunobio Find out more about the program: https://lnkd.in/e8mtWrpB Venture Leaders Biotech is organized by Venturelab in partnership with #Swissnex in Boston and supported by Debiopharm, EPFL, ETH Zürich, Hansjörg Wyss, Kellerhals Carrard Startup & VC Desk, Novartis, Swiss Biotech Association, and VISCHER. #VLeadersBiotech #SwissStartups #ConnectingTomorrow

Biotech startups often require substantial initial capital to support extensive research and development, clinical trials, and regulatory approvals before generating any revenue.   Our Investment Director, Michael Salako PhD MBA, recently spoke to Labiotech.eu, offering his advice to biotech startups trying to navigate the complex funding landscape.   When tackling the VC landscape, Michael advises biotech startups to be cautious and organised. “They should have a light touch non-confidential deck to send out and set the scene and a longer, more technical non-confidential deck that they can quickly talk to on a call if afforded the chance."   For more practical advice on choosing the right approach, read the full article here: https://rb.gy/smbt2h   #Biotech #StartUps #Funding #Fund #VentureBuilder